ERCC1-C19007T基因多态性与中晚期食管癌铂类药物化疗敏感性的Meta分析

Association between C-19007T polymorphism of ERCC1 gene and sensitivity to platinum based chemotherapy in advanced esophageal cancer: A meta-analysis

目的定量分析中晚期食管癌患者切除修复交叉互补基因1(excision repair cross complementing1,ERCC1)C-19007T基因多态性与铂类药物化疗敏感性的关系.方法计算机检索PubMed、EMBASE、Cochrane Library,中文科技期刊数据库、中国生物医学文献数据库、中国期刊全文数据库和万方数据库,收集有关中晚期食管癌患者ERCC1-C19007T基因多态性与基于铂类药物方案化疗敏感性的相关研究,以临床化疗有效率(完全缓解+部分缓解)作为化疗敏感评价指标,采用Reviewm5.2及Stata12.1软件进行统计学分析,计算合并比值比(odd ratio,OR)及95%可信区间(confi dence interval,CI).结果本研究共纳入8篇文献.Meta分析结果显示,各基因型之间(CT vs CC:OR=3.31,95%CI:1.94-5.64);(CT vs TT:OR=5.48,95%CI:3.21-9.35);(CT vs CC+TT:OR=4.06,95%CI:2.66-6.18);差异有统计学意义,表明ERCC1-C19007T基因多态性与中晚期食管癌对铂类化疗药物敏感性的差异有统计学意义.结论ERCC1-C19007T基因多态性可能与食管癌铂类药物化疗耐药相关.

AIM To evaluate the association between C-19007 T polymorphism of the excision repair cross complementing 1（ERCC1） gene and sensitivity to platinum based chemotherapy in advanced esophageal cancer.METHODS Relevant published studies were retrieved from PubMed, EMBASE, Cochrane Library,Chinese Science and Technology Periodicals Data, Chinese Biomedical Literature Data, and China National Knowledge Infrastructure.Clinical response [complete response（CR）＋ partial response（PR）] was employed to estimate chemosensitivity. Odds ratio（OR）and its 95% confidence interval（CI） were calculated. Statistical analyses were conducted using Reviewm5.2 and Stata12.1 software.RESULTS A total of 8 trials were included in this analysis. The result of meta-analysis showed that statistical signifi cance was found between ERCC1-C-19007 T polymorphism and clinical response in genotypes CT vs CC（OR = 3.31,95%CI： 1.94-5.64）; CT vs TT（OR = 5.48, 95%CI：3.21-9.35）; and CT vs CC ＋ TT（OR = 4.06,95%CI： 2.66-6.18）.CONCLUSION Polymorphism of ERCC1-C-19007 T may be associated with non-response to platinum-based chemotherapy in advanced esophageal cancer.